Novartis PharmaBasel, Basel-Stadt, Switzerland
1428: A Post-hoc Analysis of Two Phase 2 Randomized Controlled Trials in Patients with Active Sjogren’s Disease Exploring the Novel Composite Endpoint Sjögren’s Tool for Assessing Response (STAR)
Sunday, November 17, 202410:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose